Abstract
Non-Hodgkin's lymphoma is the fifth most common cause of death due to cancer and has been rising at a rate of 4% per year for the last four decades. Although 'traditional' chemotherapy and radiotherapy have had important contributions to improving outcomes, new tools in the treatment of non-Hodgkin's lymphoma are needed. This review describes therapeutic modalities that are currently being used or are in the process of being developed and which are based on concepts divergent from 'traditional' approaches to managing non-Hodgkin's lymphoma.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 43-52 |
| Number of pages | 10 |
| Journal | Expert review of anticancer therapy |
| Volume | 1 |
| Issue number | 1 |
| DOIs | |
| State | Published - 2001 |
Keywords
- Allogeneic
- Antibiotic
- Antisense
- Autologous
- Lymphoma
- Monoclonal
- Transplantation
- Vaccine
ASJC Scopus subject areas
- Oncology
- Pharmacology (medical)